This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Company News for July 10, 2024
by Zacks Equity Research
Companies In The Article Are:INCY, LW,PATH and HELE
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
by Zacks Equity Research
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
Agilent (A) Boosts Reach to Lab Researchers With New Devices
by Zacks Equity Research
Agilent (A) boosts its presence in the mass spectrometry market with the launch of the Agilent 7010D Triple Quadrupole GC/MS System and the Agilent ExD Cell.
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
by Zacks Equity Research
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
Company News For May 14, 2024
by Zacks Equity Research
Companies In The Article Are:SQSP,INCY, WBA and GOOG.
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
by Zacks Equity Research
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Novartis (NVS) to Undertake Job Cuts in Development Department
by Zacks Equity Research
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
Agilent (A) is Set for Analytica 2024 With Advanced Products
by Zacks Equity Research
Agilent (A) plans to showcase its new products for analytical laboratories at Analytica 2024, boosting its overall product portfolio.
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
by Zacks Equity Research
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
by Zacks Equity Research
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings
by Zacks Equity Research
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Incyte (INCY) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -12.40% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?